Ciphergen and University of Kentucky Partner in the Fight Against Ovarian Cancer
Complete the form below to unlock access to ALL audio articles.
Ciphergen Biosystems, Inc. has announced the signing of a research and collaboration agreement with the University of Kentucky. The collaboration gives Ciphergen exclusive rights to license discoveries made during the agreement and is part of the University's ongoing research in ovarian cancer.
"Medical management is entirely different for an ovarian tumor of low or no malignant potential versus one that is overtly malignant," said Dr. Ueland, Assistant Professor of Obstetrics and Gynecology.
He adds, "With Ciphergen, we hope to accelerate the development of a new diagnostic approach to ovarian cancer by combining their biomarker discovery and diagnostic process with our clinical expertise."
Dr. DePriest, Associate Professor of Obstetrics and Gynecology, added, "It is vital that we further understand the protein biology of ovarian cancer as it relates to early diagnosis, prediction of clinical course, and overall outcome."
"This agreement allows us to expand our current research in oncology by working with Doctor van Nagell and his colleagues," said Gail Page, President and Chief Operating Officer of Ciphergen.
He adds, "The University of Kentucky is a major referral center for the treatment of gynecologic malignancies. We are very pleased to be collaborating in our mutual goal to develop novel diagnostics in the field of ovarian cancer."
Under the terms of the agreement, Ciphergen will provide its suite of proteomic solutions (Deep Proteome™, Pattern Track Process™ and ProteinChip® System) designed for biomarker discovery and development of assays, to analyze clinical samples collected at University of Kentucky Healthcare.
Researchers will analyze patients' tumor cyst fluid and blood, looking for specific proteins to differentiate malignant from benign ovarian conditions.
